Analytical Data
-
基因名
HCCA2
- Application
-
别名
HCCA2; HCCA2 gene; HCCA2 protein; MOB kinase activator 2; MOB2; Mob2 homolog; MOB2 Mps One Binder homolog; MOB2_HUMAN; Mps one binder kinase activator like 2; Mps one binder kinase activator-like 2
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q70IA6
-
表达区间
1-237aa
-
氨基酸序列
MDWLMGKSKAKPNGKKPAAEERKAYLEPEHTKARITDFQFKELVVLPREIDLNEWLASNTTTFFHHINLQYSTISEFCTGETCQTMAVCNTQYYWYDERGKKVKCTAPQYVDFVMSSVQKLVTDEDVFPTKYGREFPSSFESLVRKICRHLFHVLAHIYWAHFKETLALELHGHLNTLYVHFILFAREFNLLDPKETAIMDDLTEVLCSGAGGVHSGGSGDGAGSGGPGAQNHVKER
-
分子量
53.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HCCA2 recombinant protein has garnered significant interest in the field of immunology and molecular biology due to its potential applications in vaccine development and therapeutic interventions. HCCA2, an antigen typically associated with certain pathogenic bacteria, plays a critical role in eliciting immune responses. The study of HCCA2 is driven by its ability to enhance the recognition of these pathogens by the immune system, thereby contributing to the development of more effective vaccines. Recent advances in recombinant DNA technology have enabled the production of HCCA2 in heterologous expression systems, allowing for large-scale generation of purified protein suitable for research and clinical applications. Investigations into the structural and functional properties of HCCA2 recombinant protein have revealed insights into its immune epitopes and mechanisms of action, paving the way for innovative strategies in vaccine design targeting specific infectious diseases. Furthermore, ongoing research is focused on understanding how HCCA2 can be utilized in combination with adjuvants to boost immune responses, particularly in populations at high risk for infection. Through these studies, HCCA2 recombinant protein represents a promising avenue for enhancing public health outcomes by improving vaccine efficacy and broadening immunological protection against various pathogens.
